Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J
Department of Hematology/Medical Oncology, Cleveland Clinic Foundation, Ohio 44195, USA.
Gynecol Oncol. 1996 Mar;60(3):435-7. doi: 10.1006/gyno.1996.0069.
In an effort to develop a cost-effective antiemetic regimen for carboplatin-based chemotherapy, we examined a fixed (0.5 mg) low dose of granisetron (a new 5-HT3 (serotonin) antagonist) plus dexamethasone (20 mg) in 23 patients with gynecologic malignancies receiving this antineoplastic drug. Nineteen (83%) patients experienced complete control of acute emesis (nausea and vomiting) while 22 (96%) individuals demonstrated complete or major control (< or = 2 episodes of vomiting, < or = 5 episodes of retching, minimal interference with eating) of emetic events. We conclude that this fixed low-dose granisetron plus dexamethasone regimen is a safe, convenient, and cost-effective antiemetic program for individuals receiving carboplatin-based chemotherapy.
为了开发一种用于基于卡铂的化疗的经济有效的止吐方案，我们对23例接受这种抗肿瘤药物治疗的妇科恶性肿瘤患者，使用了固定低剂量（0.5毫克）的格拉司琼（一种新型5-羟色胺3（血清素）拮抗剂）加地塞米松（20毫克）进行了研究。19名（83%）患者的急性呕吐（恶心和呕吐）得到完全控制，而22名（96%）患者的呕吐事件得到完全或主要控制（呕吐少于或等于2次，干呕少于或等于5次，对进食干扰最小）。我们得出结论，对于接受基于卡铂的化疗的患者，这种固定低剂量的格拉司琼加地塞米松方案是一种安全、方便且经济有效的止吐方案。
